In attendance:

<table>
<thead>
<tr>
<th>In attendance:</th>
<th>RSNA:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Goldmacher, MD, PhD, MBA (Co-Chair)</td>
<td>Lubomir Hadjiiski, PhD</td>
</tr>
<tr>
<td>Maria Athelogou, PhD</td>
<td>Edward Jackson, PhD</td>
</tr>
<tr>
<td>Hubert Beaumont, PhD</td>
<td>Rudresh Jarecha, MBBS</td>
</tr>
<tr>
<td>Andrew Buckler, MS</td>
<td>Claudia Kirsch, MD</td>
</tr>
<tr>
<td>Heang-Ping Chan, PhD</td>
<td>Yongguang Liang, PhD, DABR</td>
</tr>
<tr>
<td>Charles Fenimore, PhD</td>
<td>Eleni Liapi, MD, ScM</td>
</tr>
<tr>
<td>Matthew Fuld, PhD</td>
<td>James Mulshine, MD</td>
</tr>
</tbody>
</table>

Review prior call summary: March 13<sup>th</sup> summary approved as submitted

Discussion included the following:

**QIDW:**
- All FDA LungMan Phantom and DRO data have been uploaded to the QIDW
- Mr. O’Donnell to add some descriptive text and a link to the data in the Profile

**Modulation Transfer Function (MTF) language:**
- Drs. Supanich, Robins, and Samei to develop some Modulation Transfer Function (MTF) and Z-axis resolution language in the Profile Checklist to aid technologists
- This will be added to the 2018 or next version of the Profile
- The current 2017 version of the Profile is now considered at Stage #3 “technically confirmed”

**Site Feasibility Test Results (Section 4.4):**
- Dr. Fenimore is acquiring additional imagery to complete Beta testing the Duke CT 233 software to check for reasonable levels of agreement
- He is comparing the original method of determining contrast resolution subjectively via a line pairs per cm measurement (measurements referenced in the Profile) to currently used MTF measurements that are determined by algorithm
- His goal is to determine whether or not the MTF thresholds are conformant
- It is necessary to see whether or not the Profile has based answers on a previously used method which may not have practical application now
- He is working offline with Drs. Samei and Robins to clarify technical changes
- Changes in measurements utilizing MTF will need to be tested during claim confirmation

**Checklist Update**
- Dr. Gill provided an updated checklist to the BC Co-chairs and Drs. Kirsch and Tang for review, to include some clarifying language for technologists
- Suggestions included:
  - Adding information regarding the need for a user name and password for the QIDW
  - Need for an attached Excel spreadsheet when responding to the conformance questions
    - Mr. Tervé is working on creating an expanded spreadsheet that allows users to enter their data for automatic tabulation and response regarding conformance
    - Spreadsheet to be downloaded with each dataset
  - Time to download all 31 cases and review them
- Length of time for full case review is still needed
  - Clarification needed regarding differences between site qualification and tasks geared only toward patients
- Separating the checklist out into tabs by actor might be helpful to users

**Conformance Checklist Feedback Table**
- Mr. O’Donnell is collating all conformance/field testing feedback into a single spreadsheet for group review, similar to the public comment review process
- Comments have been received from Duke, Rush/U Chicago, Columbia, and Brigham & Women’s
- Items that no site was able to meet should be given priority for resolution
- Questions were raised as to whether “challenging” checklist requirements should be relaxed and if this would weaken the claim, i.e. lower the performance bar too much
- Mr. O’Donnell plans to revise the checklist format to improve future cut and paste functions

**Second Round of Conformance/Field Testing**
- Because none of the testers have tried using the LungMan Phantom data or DRO yet, a full scale Profile run-through was not attempted
- Proposed was an additional round of field testing, where 1-2 volunteer sites could now assess the completed Profile; however, it may be difficult to find these volunteers
- Dr. Liang volunteered to try this additional testing once he has access the LungMan Phantom and DRO data

**For discussion on next call:**
- After resolution of comments: Should two or more sites be asked to complete the entire Profile or should feedback resolution be accepted based on the current, incomplete testing

**Action items:**
- Dr. Fenimore to provide results of CT 233 testing on next call
- Additional spreadsheets for a regression module as well as for the coordinates for the RIDER tumors are being compiled by Mr. Tervé
- Drs. Samei, Robins, and Supanich to collaborate on Z–axis resolution and Modulation Transfer Function (MTF) language for the Profile
- Those interested in a Texture/ Morphology TF are asked to email the co-chairs or RSNA Staff: jlisiecki@rsna.org

**Next Call:** Monday, March 27, 2017 at 11 am CT – (Biomarker Committee)